A small trial with AD patients receiving intravenous insulin revealed that APOE ε4 non-carriers Had lower APP levels when insulin levels reached 85 μU/ml, whereas individuals carrying one APOE ε4 allele showed increased APP levels [308]. This evidence concerns the gene APP and Alzheimer disease.